Trade

with

Johnson & Johnson
(NYSE: JNJ)
AdChoices
101.22
+0.86
+0.86%
After Hours :
101.30
+0.08
+0.08%

Open

101.10

Previous Close

100.36

Volume (Avg)

9.36M (7.09M)

Day's Range

100.52-101.79

52Wk Range

86.09-108.77

Market Cap.

283.04B

Dividend Rate (Yield )

2.80 (2.71%)

Beta

0.57

Shares Outstanding

2.82B

P/E Ratio (EPS)

18.55 (5.41)

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
Industry Drug Manufacturers – Major
Highlights
Analyst Recommendation: Outperform
    • Revenue

    • 71.31B

    • Net Income

    • 13.83B

    • Market Cap.

    • 283.04B

    • Enterprise Value

    • -

    • Net Profit Margin %

    • 21.15

    • PEG (Price/Earnings Growth) Ratio

    • 3.33

    • Beta

    • 0.57

    • Forward P/E

    • 16.03

    • Price/Sales

    • 3.92

    • Price/Book Value

    • 3.63

    • Price/Cash flow

    • 14.60

      • EBITDA

      • 20.06B

      • Return on Capital %

      • 11.99

      • Return on Equity %

      • 21.06

      • Return on Assets %

      • 11.99

      • Book Value/Share

      • 27.67

      • Shares Outstanding

      • 2.82B

      • Last Split Factor (Date)

      • -

      • Last Dividend (Ex-Date)

      • 0.70 (11/21/2014)

      • Dividend Declaration Date

      • 10/16/2014

      Analyst Recommendation
      10/21/2014
      Outperform
        • 1 Year Price Target

        • 104.00

        • Credit Rating

        • AAA

        • Analysts

        • 5

        • EPS Estimate

        • 5.99

        • Cashflow Estimate

        • 7.72

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

        • Industry

          • Sales (Revenue)

            Q/Q (last year)

          • 9.10

          • 0.89

          • Net Income

            YTD/YTD (last year)

          • 27.40

          • 7.80

          • Net Income

            Q/Q (last year)

          • 12.90

          • 4.50

          • Sales (Revenue)

            5-Year Annual Average

          • 2.27

          • 6.10

          • Net Income

            5-Year Annual Average

          • 1.30

          • 3.73

          • Dividends

            5-Year Annual Average

          • 7.61

          • 2.17

          • Profit Margins (%)

          • Company

          • Industry

            • Gross Margin

            • 69.01

            • 69.92

            • Pre-Tax Margin

            • 23.75

            • 21.84

            • Net Profit Margin

            • 21.15

            • 18.37

            • Average Gross Margin

              5-Year Annual Average

            • 69.00

            • 71.90

            • Average Pre-Tax Margin

              5-Year Annual Average

            • 22.80

            • 21.92

            • Average Net Profit Margin

              5-Year Annual Average

            • 18.40

            • 903.40B

            • Financial Ratios

            • Company

            • Industry

              • Debt/Equity Ratio

              • 0.17

              • 0.32

              • Current Ratio

              • 2.47

              • 1.92

              • Quick Ratio

              • 1.80

              • 1.31

              • Interest Coverage

              • 35.73

              • 17.64

              • Leverage Ratio

              • 1.73

              • 2.03

              • Book Value/Share

              • 27.67

              • 14.72

              • Price Ratios

              • Company

              • Industry

                • Current P/E Ratio

                • 18.35

                • 21.88

                • P/E Ratio 5-Year High

                • 20.11

                • 193.96

                • P/E Ratio 5-Year Low

                • 10.51

                • 87.26

                • Price/Sales Ratio

                • 3.88

                • 3.70

                • Price/Book Value

                • 3.58

                • 3.69

                • Price/Cash Flow Ratio

                • 14.60

                • 13.85

                • Key Metrics

                • Company

                • Industry

                  • Return on Equity %

                    (5-Year Average)

                  • 21.06

                    (21.20)

                  • 17.42

                    (18.66)

                  • Return on Assets %

                    (5-Year Average)

                  • 11.99

                    (11.20)

                  • 8.45

                    (8.77)

                  • Return on Capital %

                    (5-Year Average)

                  • 17.80

                    (17.00)

                  • 12.41

                    (13.18)

                  • Income/Employee

                  • 121.42k

                  • 90.07k

                  • Inventory Turnover

                  • 2.85

                  • 2.46

                  • Asset Turnover

                  • 0.57

                  • 0.46

                  Current Historical
                  Financials
                  • Income Statement
                  • Balance Sheet
                  • Cash Flow
                  Operating Income
                  18.38B
                  Operating Margin
                  25.77
                  Total Equity
                  -
                  Retained Earnings
                  -
                  Free Cashflow
                  -
                  Price/Cashflow
                  14.60
                  Ownership

                  Institutional Ownership

                  68.65%

                  Top 10 Institutions

                  23.84%

                  Mutual Fund Ownership

                  31.55%

                  Float

                  99.77%

                  5% / Insider Ownership

                  0.08%

                  Corporate insiders or major stockholders reporting trading activity in the stock.

                  Top Mutual Fund Owners

                  Top Institutional Owners

                  Mutual Fund Name

                  Institution Name

                  • Mutual Fund Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Vanguard Total Stock Mkt Idx

                  •  

                    46,165,921

                  • 0.46

                  • 1.64

                  • Vanguard Five Hundred Index Fund

                  •  

                    29,279,401

                  • -0.08

                  • 1.04

                  • Vanguard Institutional Index Fund

                  •  

                    28,572,882

                  • -1.36

                  • 1.01

                  • SPDR® S&P 500 ETF

                  •  

                    27,510,258

                  • -2.11

                  • 0.91

                  • Fidelity® Contrafund® Fund

                  •  

                    18,600,672

                  • 0.57

                  • 0.66

                  • VA CollegeAmerica Washington Mutual

                  •  

                    13,930,000

                  • 0.00

                  • 0.49

                  • CREF Stock

                  •  

                    12,457,779

                  • -1.34

                  • 0.44

                  • Fidelity Spartan® 500 Index Fd

                  •  

                    12,268,606

                  • 0.14

                  • 0.44

                  • Health Care Select Sector SPDR® Fund

                  •  

                    12,181,212

                  • -1.46

                  • 0.40

                  • MFS® Value Fund

                  •  

                    12,020,805

                  • 0.00

                  • 0.43

                  • Institution Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Vanguard Group, Inc.

                  •  

                    156,359,961

                  • +3.10%

                  • 5.54

                  • State Street Corp

                  •  

                    152,623,408

                  • +1.21%

                  • 5.41

                  • BlackRock Fund Advisors

                  •  

                    87,483,808

                  • -0.89%

                  • 3.10

                  • Fidelity Management and Research Company

                  •  

                    51,087,205

                  • +17.25%

                  • 1.81

                  • Wellington Management Company, LLP

                  •  

                    45,309,314

                  • -0.38%

                  • 1.61

                  • Northern Trust Investments, N.A.

                  •  

                    40,642,281

                  • +1.41%

                  • 1.44

                  • State Farm Mutual Automobile Ins CO

                  •  

                    37,878,592

                  • 0.00%

                  • 1.34

                  • J.P. Morgan Investment Management Inc.

                  •  

                    36,420,798

                  • -2.67%

                  • 1.29

                  • MFS Investment Management K.K.

                  •  

                    33,534,752

                  • -1.45%

                  • 1.19

                  • Capital World Investors

                  •  

                    31,460,000

                  • -2.48%

                  • 1.11

                  Company Profile

                  Sector

                  Healthcare

                  Industry

                  Drug Manufacturers – Major

                  Type

                  Classic Growth

                  Style

                  Large Core

                  Johnson & Johnson was incorporated in the State of New Jersey in 1887. The Company is engaged in the research and development, manufacture and sale of a range of products in the health care field. It is a holding company, which has m...moreore than 275 operating companies conducting business in virtually all countries of the world. The Company's operating companies are organized into three business segments: Consumer, Pharmaceutical and Medical Devices and Diagnostics. The Consumer segment includes products used in the baby care, skin care, oral care, wound care and women's health care fields, as well as nutritional and over-the-counter pharmaceutical products. The Baby Care franchise includes the JOHNSON'S® Baby line of products. Major brands in the Skin Care franchise include the AVEENO®; CLEAN & CLEAR®;...more JOHNSON'S® Adult; NEUTROGENA®; RoC®; LUBRIDERM®; Beijing Dabao Cosmetics Co., Ltd.; and Vendome product lines. The Oral Care franchise includes the LISTERINE® and REACH® oral care lines of products. Major brands in the Women"s Health franchise are the CAREFREE® Pantiliners and STAYFREE® sanitary protection products. The nutritional and over-the-counter lines include SPLENDA®, No Calorie Sweetener; the family of TYLENOL® acetaminophen products; SUDAFED® cold, flu and allergy products; ZYRTEC® allergy products; MOTRIN® IB ibuprofen products; and PEPCID® AC Acid Controller from Johnson & Johnson Merck Consumer Pharmaceuticals Co. The Pharmaceutical segment includes products in the following therapeutic areas: anti-infective, antipsychotic, cardiovascular, contraceptive, dermatology, gastrointestinal, hematology, immunology, neurology, oncology, pain management, urology and virology. Key products in the Pharmaceutical segment include: REMICADE® a treatment for a number of immune-mediated inflammatory diseases; SIMPONI® (golimumab), a treatment for adults with moderate to severe rheumatoid arthritis, active psoriatic arthritis, active ankylosing spondylitis and moderately active to severely active ulcerative colitis; STELARA® a treatment for adults with moderate to severe plaque psoriasis and active psoriatic arthritis; INCIVO® for the treatment of hepatitis C; INTELENCE® and PREZISTA®, treatments for HIV/AIDS; CONCERTA® extended-release tablets CII, a treatment for attention deficit hyperactivity disorder; INVEGA® extended-release tablets, for the treatment of schizophrenia and schizoaffective disorder; INVEGA® SUSTENNA®/XEPLION®, for the treatment of schizophrenia in adults; RISPERDAL® CONSTA®, for the treatment of schizophrenia and for the maintenance treatment of Bipolar I Disorder; VELCADE®, a treatment for multiple myeloma; ZYTIGA®, a treatment for metastatic castration-resistant prostate cancer; ACIPHEX®/PARIET®, a proton pump inhibitor co-marketed with Eisai Inc.; PROCRIT®, to stimulate red blood cell production; and XARELTO®, an oral anticoagulant for the prevention of deep vein thrombosis (DVT), which may cause to pulmonary embolism (PE) in patients undergoing hip or knee replacement surgery, to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation, for the treatment of DVT and PE, and for the reduction in the risk of recurrence of DVT and PE. The Medical Devices and Diagnostics segment includes a range of products distributed to wholesalers, hospitals and retailers, used mainly in the professional fields by physicians, nurses, therapists, hospitals, diagnostic laboratories and clinics. In all of their product lines, Johnson & Johnson's operating companies compete with companies large and small, located throughout the world. The Company is subject to varying degrees of governmental regulation in the countries in which operations are conducted, and the general trend is toward increasingly stringent regulation.lessless

                  Key People

                  Alex Gorsky

                  CEO/Director/Chairman of the Board

                  Sandra E. Peterson

                  Chairman of the Board, Divisional

                  Paulus Stoffels

                  Chairman of the Board, Divisional/Chief Scientific Officer

                  Dominic J. Caruso

                  CFO/Vice President, Divisional

                  Peter Fasolo

                  Vice President, Divisional

                  • Johnson & Johnson

                  • One Johnson & Johnson Plaza

                  • New Brunswick, NJ 08933

                  • USA.Map

                  • Phone: +1 732 524-0400

                  • Fax: +1 732 214-0332

                  • jnj.com

                  Incorporated

                  1887

                  Employees

                  128,100

                  Send Feedback

                  We appreciate your input!

                  • I'm having trouble signing into my Microsoft account

                  • I’m having problems with the services stripe (Mail, Facebook, etc.)

                  • There is an issue with my weather information

                  • I see an error in the content

                  • Other

                  Please give an overall site rating: